Company intelligence / Profile preview

Changchun High-Tech

Ownership: Private
Employees: ~11547
Development stage: Commercial

Overview

The company is a leading commercial-stage biopharmaceutical group in China with a diversified portfolio including genetic engineering drugs, biological vaccines, modern Chinese medicines, and chemical/antibody drugs. It has consistently ranked among the top pharmaceutical companies in China since entering the national top 100 list in 2017.

Modalities: BiologicVaccineSmall moleculeHerbal medicineMonoclonal antibody
Industry: Pharma

Drug pipeline

5 assets

recombinant human growth hormone

Commercial

Indications: Growth hormone deficiency

4 more assets in the full pipeline.

Beyond the preview

Go deeper on Changchun High-Tech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changchun High-Tech.